Prognostic Impact of Low Estrogen and Progesterone Positivity in Luminal B (HER2 Negative) Breast Cancer

Rajc, Jasmina

doi:10.20471/acc.2018.57.03.04

Cited by 10 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to our findings, a recently published study showed that 16% of IHC ER+HER2− BCs could be reclassified as Basal molecular subtypes by multigene expression profiling 24 . Furthermore, studies showed that the ER+HER2− Basal subtype is obviously different from the ER+HER2− Luminal subtype and sometimes similar to the ER‐negative Basal subtype with regard to potential therapeutic sensitivity to systemic therapies 24–26 …”

Section: Discussionsupporting

confidence: 87%

“… 24 Furthermore, studies showed that the ER+HER2− Basal subtype is obviously different from the ER+HER2− Luminal subtype and sometimes similar to the ER‐negative Basal subtype with regard to potential therapeutic sensitivity to systemic therapies. 24 , 25 , 26 …”

Section: Discussionmentioning

confidence: 99%

“…24 Furthermore, studies showed that the ER+HER2− Basal subtype is obviously different from the ER+HER2− Luminal subtype and sometimes similar to the ER-negative Basal subtype with regard to potential therapeutic sensitivity to systemic therapies. [24][25][26] Currently, multigene expression profiles, such as Oncotype DX, MammaPrint, and Prosiga, have become widely used to predict the risk of recurrence and adjuvant chemotherapy benefits. 4,[27][28][29] However, these genomicbased classification applications are restricted in our developing countries because of the relatively higher price.…”

Section: T a B L E 5 Associations Between Clinical And Pathological F...mentioning

confidence: 99%

See 2 more Smart Citations

The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score

et al. 2022

View full text Add to dashboard Cite

Background Breast cancer (BC) remains the leading cause of cancer‐related deaths worldwide. High recurrence risk Luminal BC receives adjuvant chemotherapy in addition to standard hormone therapy. Considering the heterogeneity of Luminal B BC, a more accurate classification model is urgently needed. Methods In this study, we retrospectively reviewed the data of 1603 patients who were diagnosed with HER2‐negative breast invasive ductal carcinoma. According to the expression level of PR and Ki‐67 index, the Luminal B (HER2‐negative) BCs were divided into three groups: ER+PR−Ki67 low (ER‐positive, PR‐negative, and Ki‐67 index <20%), ER+PR+Ki67 high (ER‐positive, PR‐positive, and Ki‐67 index ≥20%), and ER+PR−Ki67 high (ER‐positive, PR‐negative, and Ki‐67 index ≥20%). The cox proportional hazards regression model was used to evaluate the correlation between each variable and outcomes. Besides, discriminatory accuracy of the models was compared using the area under the receiver operating characteristic curve and log‐rank χ 2 value. Results The analysis results showed that there was a significant correlation between subtypes using this newly defined classification and overall survival ( p < 0.001) and disease‐free survival (DFS) ( p < 0.001). Interestingly, patients in the ER+PR−Ki67 high subgroup have the worst survival outcome in Luminal B (HER2‐negative) subtype, similar to Triple‐negative patients. Besides, the ER+PR+Ki67 high has worse 5‐year DFS compared with Luminal A group. There was a significant relationship between the regrouping subtype and the recurrence score index (RI) ( p < 0.001). Moreover, the results showed that patients in ER+PR–Ki67 high subtype were more likely to have high RI for distance recurrence (RI‐DR) and local recurrence (RI‐LRR). Our newly defined classification has a better discrimination ability to predict survival outcome and recurrence score of Luminal B (HER2‐negative) BC patients, which may help in clinical decision‐making for individual treatment.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Section: T a B L E 5 Associations Between Clinical And Pathological F...mentioning

confidence: 99%

See 1 more Smart Citation

The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score

et al. 2022

View full text Add to dashboard Cite

show abstract

“…According to St. Gallen Breast Cancer Conference, they are divided into 5 subgroups: Luminal A, Luminal B HER2 negative (LUM B1), Luminal B HER2 positive (LUM B2), HER2 positive (HER2 pos) and triple negative subtype. This division is based on estrogen (ER) and progesterone (PR) receptor and human epithelial growth factor expression ( 5 , 6 ). This classification includes all breast cancer types regardless of their histopathologic group.…”

Section: Introductionmentioning

confidence: 99%

Serum Leptin Level in Breast Cancer

Koprivčić¹,

Marjanović²,

Matić³

et al. 2022

acc

View full text Add to dashboard Cite

Leptin is a polypeptide which is mostly produced in white fat tissue and is an important proinflammatory, proangiogenic, proinvasive and mitotic factor. There is ever more evidence suggesting the key role of leptin in the occurrence of breast cancer. The aim of the study was to investigate serum leptin levels in patients with benign breast tumors, as well as in various breast cancer phenotypes, taking into account leptin levels connected to menopausal status and body mass index (BMI). The study included 97 patients having their breast tumor surgically removed. Serum leptin level was determined by ELISA method in all study patients. Study results showed that significantly more women, regardless of having malignant or benign tumors, were postmenopausal and had a significantly higher level of leptin compared to the premenopausal group. The highest level of leptin was recorded in the group of postmenopausal obese women compared to other postmenopausal women but also compared to premenopausal women. According to BMI alone, obese women had a significantly higher level of leptin regardless of the type of tumor. The most significant differences in leptin levels observed through BMI were found in the Luminal B1 group. In conclusion, serum leptin level was shown to be a good diagnostic parameter suggesting a higher possibility of breast cancer development.

show abstract

“…Not surprisingly, PR expression serves as a predictive parameter for endocrine therapy response [ 47 ]. In many cases, as HR+ tumors progress, many lose ER and/or PR expression and, as such, loss of PR expression is associated with a significantly worse prognosis [ 47 , 49 ]. Several studies have indicated that PR loss contributes to an aggressive phenotype as a result of activating a transcriptomic profile which includes increased EGFR and NOTCH1 signaling as well as expression of genes that regulate amino acid uptake.…”

Section: Introductionmentioning

confidence: 99%

Nuclear Receptor-Mediated Metabolic Reprogramming and the Impact on HR+ Breast Cancer

Hussein

Khanna

Yunus

et al. 2021

Cancers

View full text Add to dashboard Cite

Metabolic reprogramming enables cancer cells to adapt to the changing microenvironment in order to maintain metabolic energy and to provide the necessary biological macromolecules required for cell growth and tumor progression. While changes in tumor metabolism have been long recognized as a hallmark of cancer, recent advances have begun to delineate the mechanisms that modulate metabolic pathways and the consequence of altered signaling on tumorigenesis. This is particularly evident in hormone receptor positive (HR+) breast cancers which account for approximately 70% of breast cancer cases. Emerging evidence indicates that HR+ breast tumors are dependent on multiple metabolic processes for tumor progression, metastasis, and therapeutic resistance and that changes in metabolic programs are driven, in part, by a number of key nuclear receptors including hormone-dependent signaling. In this review, we discuss the mechanisms and impact of hormone receptor mediated metabolic reprogramming on HR+ breast cancer genesis and progression as well as the therapeutic implications of these metabolic processes in this disease.

show abstract

Prognostic Impact of Low Estrogen and Progesterone Positivity in Luminal B (HER2 Negative) Breast Cancer

Cited by 10 publications

References 19 publications

The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score

The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score

Serum Leptin Level in Breast Cancer

Nuclear Receptor-Mediated Metabolic Reprogramming and the Impact on HR+ Breast Cancer

Contact Info

Product

Resources

About